Sanofi announced it has completed the acquisition of Vigil Neuroscience, Inc., a move aimed at strengthening its position in neurology and rare neurodegenerative diseases. The all-cash transaction is valued at approximately $822 million.
According to the company, the acquisition will add Vigil’s pipeline to Sanofi’s portfolio, including VGL101, a monoclonal antibody currently in a Phase 2 trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). This rare, genetic, and fatal neurodegenerative disease is caused by mutations in the CSF1R gene.
The company said the deal also includes rights to Vigil’s preclinical program, VG-3927, a small-molecule CSF1R inhibitor in development for rare microgliopathies. Sanofi claims these programs complement its existing work in neurology and align with its strategy to focus on first- or best-in-class medicines in specialty care.
Sanofi stated that the integration of Vigil’s programs is expected to accelerate the development of potential treatments for underserved patient populations with high unmet medical needs. The company highlighted that rare neurodegenerative conditions often have limited or no approved therapies, making them a key area of focus for future research and development.
The acquisition, first announced in June 2025, has now received all necessary approvals and is effective immediately. Sanofi said it will continue advancing the clinical and preclinical programs, with the goal of delivering new therapeutic options in the coming years.
